Navigation Links
Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
Date:10/16/2007

has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including Genzyme's expectations regarding the timing for FDA action on its NDA seeking approval for the use of Renvela in dialysis patients, its plans to pursue approval of Renvela for treatment of CKD patients who are not on dialysis in the US and for dialysis and pre-dialysis patients globally, including expected filings in Europe and Latin America in 2008, and its clinical study plans. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward- looking statements. These risks and uncertainties include, among others, the possibility that the FDA action with respect to the Renvela NDA is not favorable or is delayed, the possibility that Genzyme's plans for Renvela use in pre-dialysis patients will not be successful, and the possibility that regulatory authorities outside the US do not grant marketing authorization for the use of Renvela in
'/>"/>

SOURCE Genzyme
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Genzyme Announces First Phase III Study of Tolevamer in Diarrhea Patients
2. Fresh warnings to doctors regarding abortion pill
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Will anxiety regarding fertility treatment affect the chances of conception?
5. Changing Trends Regarding Insurance Cover For Weight Reduction Surgery
6. Indian Government warns Gujarat regarding possibility of bird flu
7. Leeches Provide Clues Regarding The Prevention Of Heart Disease
8. AIDS control requires co-coordinated move regarding safe sexual practices
9. Legal Action against Authority Regarding Outbreak of Legionnaires’ Diseas
10. Mixed Opinion Regarding Common Medical And Engineering Entrance Test
11. Adolescents Influenced By Maternal Attitude Regarding Weight Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... When looking at the types of people ... into one of two categories: those that have a weak appetite or those that have ... still want to gain weight, CB-1 Weight Gainer gives three tips for slowing down metabolism. ...
(Date:9/3/2015)... ... ... James Earl Jones will be hosting an upcoming VOICES IN AMERICA segment that highlights ... segment that discusses why it is important for the workplace to be healthier, the ... working environment. , Employers are out billions of dollars year after year due to ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... distribution channels and efficient customer and technical support services to promote LodonalTM in ... 90-day Bridging trial evaluating the efficacy and safety of the product. , Managing ...
(Date:9/2/2015)... ... 03, 2015 , ... Leah Binder, MA, MGA, president and ... in healthcare, will offer the keynote address at the upcoming meeting of the ... Palm Harbor, Florida, at the Innisbrook Resort and Golf Club. For an agenda ...
(Date:9/2/2015)... ... 03, 2015 , ... Each year, the editors of Modern ... activists, corporate executives, entrepreneurs, health care professionals, and others have had the most ... magazine to tap the National League for Nursing’s outspoken CEO, Beverly Malone ...
Breaking Medicine News(10 mins):Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3
... insomnia might increase one's chances of developing anxiety disorders and ... and goes away without treatment in many people. However, factors ... that might last for several weeks and if left untreated ... ,The study was conducted by a team of researchers ...
... has demonstrated that giving a test only once isnt enough ... It appears that repeating tests over a short period may ... ,Salthouse gave 16 common cognitive and neuropsychological tests ... the second) into groups of ages 18-39, 50-59 and 60-97 ...
... Dr. Douglas Black (UCLA) and colleagues detail how alternative ... ,Alternative splicing refers to the processing of an RNA ... and excluding others. Specific cell types often have signature ... (PTB) is a well-known inhibitor of alternative splicing in ...
... identified Variations in two genes related to inflammation may ... The effect of these genes is especially strong ... important in modulating the damage caused by tobacco smoke. ... Cancer Research, is the first to pinpoint the mechanism ...
... to 24 in the UK are so ignorant about HIV, that they ... ,The poll was conducted to mark the 25th death anniversary ... of an AIDS-related illness in England in 1982. ,About a ... condoms actually initiate the growth of HIV as they have holes that ...
... has revealed that girls as young as 15 are resorting to ... ,The Amphetamine drugs that are snorted and injected ... calories. ,Robin Herne with Suffolk's Drug and Alcohol Action ... meals. ,Herne warned that the drug can lead to ...
Cached Medicine News:Health News:Cognitive Test Takers and Score Variation 2Health News:Gene Variation Increases the Risk of Lung Cancer 2
(Date:9/2/2015)... 2015  Research and Markets ( http://www.researchandmarkets.com/research/rf2c5p/an_introduction ) ... Introduction to the Medical Devices Directive (London, UK ... offering. This seminar provides a ... It will explain the Directives and which products ... to choose one and outline what a manufacturer ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Therapeutic ... to their offering. This report deals ... aimed at improving patient care by monitoring drug ... dose of drugs for improving outcome. TDM is ...
(Date:9/2/2015)... 2, 2015  Boca Raton Regional Hospital,s ... performing ultra-minimally invasive left atrial appendage ligation for ... as Coumadin, Xarelto or Effient. Dr. Cartledge, who ... is one of a select group of surgeons ... microscopic incisions in order to seal off the ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3
... Oct. 6 According to Millennium Research Group ... intelligence, growth in the $2 billion US cardiac ... the expanded approval of Boston Scientific,s chronic resynchronization ... I and II patients. The New ...
... Oct. 6 e-MDs, an industry leader in ... (EHRs) and practice management (PM) solutions,  congratulates  the ... Family Medicine of Fort Collins, CO, for their ... of Excellence recipients.  The Healthcare Information and Management ...
Cached Medicine Technology:Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators 2Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators 3e-MDs Clients Win HIMSS Davies Awards of Excellence 2e-MDs Clients Win HIMSS Davies Awards of Excellence 3e-MDs Clients Win HIMSS Davies Awards of Excellence 4
... XT® the only fully automated slide ... need to expand your test menu, ... slide turnaround time. All with no ... to use the BenchMark XT® to ...
... and the University of Washington offer ... online for the clinical lab and ... and continuing education include Safety, Phlebotomy, ... Competency Assessment tests feature high-resolution specimen ...
... 1939, AMT has become one of ... clinical laboratory practitioners and other allied ... Medical Technologists, Medical Laboratory Technicians, Office ... Medical and Dental Assistants and Allied ...
... and Quality Assurance (for Waived and PPM ... clinics and small hospitals maintain laboratory excellence. ... patient lab results and assist labs in ... to earn 12 P.A.C.E. Contact hours per ...
Medicine Products: